Mindset Pharma Inc. Completes $4.17 Million Private Placement

December 15, 2020

Mindset Pharma Inc. (“Mindset”), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders, completed a brokered private placement of units for aggregate gross proceeds of approximately $4.17 million (the “Offering”). Each unit consisted of one common share of Mindset and one common share purchase warrant. Each warrant entitles the holder to purchase an additional common share at an exercise price of $0.60 until December 15, 2022.

The Offering was led by Mackie Research Capital Corporation (“Mackie”) as sole agent and bookrunner.

Wildeboer Dellelce LLP acted for Mackie in connection with the Offering with a team that consisted of Jeff Hergott, Niall Sweeney and Nickolas Robelek (corporate/securities).